CTLA-4-Mediated inhibition of early events of T cell proliferation.
about
Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activationModulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptorsCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaMultiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseasesInduction of CD4(+) Regulatory and Polarized Effector/helper T Cells by Dendritic CellsThe Role of Alternative Splicing in the Control of Immune Homeostasis and Cellular DifferentiationImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?CD28 and CTLA-4 coreceptor expression and signal transductionImmune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammationCD152 (CTLA-4) determines CD4 T cell migration in vitro and in vivo.Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyCheckpoint inhibitors in hematological malignanciesDual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice.Signal peptide cleavage is essential for surface expression of a regulatory T cell surface protein, leucine rich repeat containing 32 (LRRC32).Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanomaRegulatory T cells phenotype in different clinical forms of Chagas' diseaseCTLA-4 down-regulates the protective anticryptococcal cell-mediated immune responseSingle-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalCD28, CTLA-4 and their ligands: who does what and to whom?Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor.Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction.Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation.Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitAutoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II studyAnalysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.Proliferative capacity and cytokine production by cells of HIV-infected and uninfected adults with different helminth infection phenotypes in South AfricaExpression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.Polymorphic sites at the immunoregulatory CTLA-4 gene are associated with chronic chagas disease and its clinical manifestations.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabPinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cellsCytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells.Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergySignaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.
P2860
Q21560870-B756AFA2-218A-431F-9A77-6169A777779DQ24535662-260185D6-35C6-4FE5-A2F9-6D9F5A5B38CFQ24679736-1427F8AE-A7BC-4D3E-9DF9-8AE77389A8CBQ24793730-B5569324-00D4-44E5-99CF-77C52CAD4AF3Q26764866-C48ECCE6-6EE6-40A3-80B2-F430A43641D1Q26772026-3CE60E37-C68D-483B-ADFE-D601ABDCB6DFQ27003955-FA912E8D-A3BD-4426-89EE-C1B6FD611A74Q28244243-53B12BE7-E479-4799-8150-1D8CC6CADB82Q28298280-3C47A643-3544-4B61-A4E4-A01ABA2E5E00Q33455698-7C643BE8-BD1F-47A8-A06F-FDC00445DF26Q33522281-73B780EE-DBE8-4314-97F0-01C2D2ECA308Q33651495-4992F32C-2A13-44E2-A74A-B60451B0399BQ33667690-84E51F6E-EDBC-4D9A-A926-008AB6D6C55BQ33854444-8609960D-8060-42E1-9C9A-DE7FF643C2CCQ33913016-734667B1-181D-42DC-9CB3-BA39DAFD96E8Q33924781-A4D17413-1380-470F-AEA2-131D042AFC6BQ33927456-3AEC89EE-B08F-4B32-B6CD-9C3A0C5DFEEDQ34007765-D2278887-985C-4EB2-9374-1E812620C73BQ34048270-70FE4591-932C-4BEC-9E48-53D8CBB98D23Q34049974-157A266D-31DE-4D72-97EC-77603C4C3B4BQ34050208-F7DE767A-F912-411C-A1DF-0E1C3B80D836Q34070579-FBE07903-0456-49B6-9C45-2607C76A2DA7Q34077092-8D91C983-5262-4FE7-BF64-C12CC561B727Q34476955-B8EB5468-70F9-4A74-A005-FE14B3D35811Q34561877-7279D3D6-D6D3-4F2C-BF24-4582BACD3B2AQ34601772-B73E198B-ABB9-48D6-9225-42A574D1B9E9Q34657638-AB3E65C4-D1EE-4027-A1F2-AC51336A4632Q34657668-54611361-39B4-4312-9783-8FEE0410E986Q34657684-D30C6966-11E1-4271-B16E-3DFC092C89A5Q34670441-23DE36D6-2C3F-4BD7-8815-3C4E5F2E5DE0Q34699537-9F1EA49F-1EC9-4F09-B63D-BE43154E2654Q34788858-E28C7676-A1BC-4942-8939-64ED07EC7E7DQ34925487-ECDAAF0E-8242-412A-9FCD-B55BAC0732F1Q35036373-A5D5C76D-4ECD-4B89-BE38-D18B2BCBC86EQ35289145-FDA71E89-E59D-49A0-BC90-AEEC64E8F6F1Q35405162-3B919247-D6BA-40B5-AA36-E040C728B17BQ35557344-7653C5CD-7EE0-43B5-BEBE-AA13EDDDE255Q35823170-72CB031A-3DE1-4935-9EEF-65F2DCC446A1Q35920663-5495DF3A-EAE9-46A2-866F-1C72F577E1AAQ36041455-4F2F407B-737B-4107-9FCA-0DD150E63266
P2860
CTLA-4-Mediated inhibition of early events of T cell proliferation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
CTLA-4-Mediated inhibition of early events of T cell proliferation.
@en
type
label
CTLA-4-Mediated inhibition of early events of T cell proliferation.
@en
prefLabel
CTLA-4-Mediated inhibition of early events of T cell proliferation.
@en
P2093
P1476
CTLA-4-Mediated inhibition of early events of T cell proliferation
@en
P2093
P304
P407
P577
1999-05-01T00:00:00Z